Left Atrial Appendage Closure When Anticoagulation Is Not an Option
Atrial fibrillation is associated with a substantial risk of thromboembolic stroke, and oral anticoagulation remains the standard preventive treatment for most patients with elevated risk. Yet anticoagulants can become unsuitable when a patient has recurrent major bleeding, an intracranial hemorrhage history, severe frailty, high-risk gastrointestinal pathology, or another persistent contraindication.
Left atrial appendage closure offers a device-based strategy for selected people with nonvalvular atrial fibrillation. By excluding the appendage, where most atrial fibrillation-related thrombi form, the procedure seeks to reduce embolic risk without requiring indefinite systemic anticoagulation. It does not remove all stroke mechanisms, and careful selection remains central.
The decision requires collaboration among electrophysiologists, structural heart specialists, neurologists, hematologists, and the patient. Assessment should address the reason anticoagulation cannot be used, the durability of that contraindication, procedural risk, anatomy, life expectancy, and the feasibility of short-term antiplatelet treatment.
Identifying Appropriate Candidates
The clearest candidates have nonvalvular atrial fibrillation, a meaningful risk of ischemic stroke, and a contraindication to long-term oral anticoagulation that is clinically compelling. Stroke risk is commonly estimated with the CHA₂DS₂-VASc score, while bleeding risk tools can identify modifiable hazards. These scores support discussion but should not replace individualized judgment.
A prior bleeding event does not automatically make anticoagulation impossible. Clinicians should determine whether the cause can be corrected, such as uncontrolled hypertension, a treatable gastrointestinal lesion, excessive alcohol use, or an interacting medication. Conversely, recurrent bleeding from an irreversible source or a previous spontaneous intracranial hemorrhage may support consideration of an occlusion device.
Patients must understand that left atrial appendage closure is an alternative to chronic anticoagulation, not a universal replacement for every antithrombotic therapy. Some individuals still need antiplatelet medication after implantation, and anticoagulation may be used briefly depending on the device, imaging findings, thrombotic risk, and local protocol.
How Appendage Exclusion Reduces Embolic Risk
The left atrial appendage is a trabeculated structure that can promote blood stasis during atrial fibrillation. Device closure places a seal at its opening, aiming to prevent thrombus from entering the systemic circulation. The approach is particularly relevant when the appendage is the principal suspected source of embolism and long-term anticoagulation has an unfavorable safety profile.
Most procedures are performed percutaneously through transseptal access under fluoroscopic and echocardiographic guidance. Preprocedural computed tomography or transesophageal echocardiography helps define ostium dimensions, depth, orientation, thrombus status, and surrounding anatomy. A suitable landing zone is essential for stable deployment and complete sealing.
Several commercially available systems use different anchoring and sealing principles. Device choice depends on appendage morphology, ostial size, depth, septal puncture position, operator experience, and the ability to accommodate residual leaks. Surgical or thoracoscopic exclusion may be considered when a patient is already undergoing cardiac surgery, although it represents a different procedural pathway.
Evidence From Trials and Registries
Early randomized studies established the concept that percutaneous appendage closure could provide stroke prevention comparable to warfarin in selected patients with atrial fibrillation. Later studies and registries expanded experience in patients with bleeding concerns, advanced age, renal disease, and other factors that often limit routine anticoagulation. The evidence base is strongest for carefully selected nonvalvular atrial fibrillation rather than for all causes of embolic stroke.
Observational studies of people considered unsuitable for long-term anticoagulation have generally reported lower-than-expected rates of ischemic stroke and acceptable procedural safety. However, registries may be affected by selection bias, differences in antithrombotic regimens, and variable follow-up. Comparisons with direct oral anticoagulants are also difficult because many pivotal device trials were designed before current anticoagulation practice became widespread.
| Clinical consideration | Why it matters | Questions for the care team |
|---|---|---|
| Stroke risk | Determines the expected benefit of embolic prevention | Is the patient’s risk high enough to justify an invasive procedure? |
| Reason for anticoagulation intolerance | Distinguishes a durable contraindication from a reversible problem | Can the bleeding source or medication interaction be corrected? |
| Appendage anatomy | Affects feasibility, device selection, and sealing | Is there thrombus, insufficient depth, or an unsuitable landing zone? |
| Short-term medication tolerance | Most patients need temporary antithrombotic therapy | Can the patient safely take antiplatelet treatment after implantation? |
| Procedural risk | Includes tamponade, vascular injury, embolization, and anesthesia-related events | Does the anticipated benefit exceed the near-term procedural hazard? |
| Follow-up capacity | Imaging is needed to assess seal and device-related thrombus | Can the patient return for transesophageal echo or cardiac CT? |
The balance between stroke prevention and bleeding reduction should therefore be presented transparently. Shared decision-making is especially important for older adults, patients with competing illnesses, and those whose contraindication is based on a single remote event rather than an ongoing hazard.
Medication Strategy After Implantation
Antithrombotic treatment after closure is individualized because the device surface may be thrombogenic before endothelialization. Historically, some protocols used short-term warfarin followed by antiplatelet therapy, while other pathways use a direct oral anticoagulant or dual antiplatelet therapy. In patients with a true contraindication to anticoagulation, clinicians may consider antiplatelet-only regimens when supported by the device instructions, available evidence, and bleeding profile.
The treatment plan should be documented before the procedure. It should specify the medication, dose, duration, response to bleeding, and the imaging milestone that will guide de-escalation. Aspirin and clopidogrel can also cause clinically important bleeding, so “no anticoagulation” does not mean “no medication risk.”
Follow-up imaging, commonly with transesophageal echocardiography or cardiac CT, evaluates peri-device leak, device position, and device-related thrombus. A significant leak or thrombus may require prolonged therapy, repeat imaging, or another intervention. Decisions should be made by the implanting team in conjunction with the clinician managing the original bleeding problem.
Managing Procedural Risk and Long-Term Outcomes
Important early complications include pericardial effusion or tamponade, vascular complications, air embolism, stroke, device embolization, and anesthesia-related events. Improvements in imaging, delivery systems, operator training, and patient selection have reduced complication rates, but the procedure remains invasive. A preimplantation scan and meticulous transseptal technique help reduce avoidable hazards.
Device-related thrombus is uncommon but clinically important because it can cause embolic events. Risk may be higher with persistent atrial fibrillation, larger appendage anatomy, low-flow states, renal dysfunction, and inadequate antithrombotic protection. New neurological symptoms, unexplained hypotension, chest pain, or worsening dyspnea after the procedure require urgent evaluation.
Long-term management still includes treatment of other stroke risks. Blood pressure control, diabetes management, smoking cessation, sleep apnea evaluation, and vascular risk reduction remain relevant. Closure also does not eliminate atrial fibrillation symptoms or the need to assess rate control, rhythm control, ablation, or device-based pacing when indicated.
Pericardial disease deserves particular attention in patients with prior cardiac procedures or inflammatory conditions. A review of recurrent pericarditis after ablation illustrates why postprocedural chest symptoms should be assessed carefully rather than attributed automatically to benign recovery.
Integrating Closure Into Shared Decisions
A high-quality decision begins with a structured review of alternatives. The team should compare continued anticoagulation, a modified anticoagulant strategy, antiplatelet treatment, appendage closure, and—when relevant—surgical exclusion. The discussion should include absolute risks, expected longevity, recovery time, medication requirements, and the possibility that closure will not fully prevent stroke.
Patients should receive clear information about the technical steps and follow-up pathway. This includes the need for preprocedural imaging, anesthesia or sedation, temporary restrictions after femoral access, medication adherence, and surveillance imaging. A patient who cannot attend follow-up or take any postprocedural therapy may be a poor candidate even if the appendage anatomy is favorable.
Practical recommendations for multidisciplinary care include:
- Confirm that the indication involves nonvalvular atrial fibrillation and a meaningful thromboembolic risk.
- Investigate whether the stated anticoagulation contraindication is persistent, severe, and not reasonably reversible.
- Use transesophageal echocardiography or cardiac CT to exclude thrombus and plan device selection.
- Agree on a postimplant antithrombotic regimen before the procedure, including a contingency plan for bleeding.
- Arrange documented follow-up imaging and reassess stroke, bleeding, rhythm, and cardiovascular risk over time.
The most reliable outcomes come from programs that maintain a consistent pathway from referral through surveillance. Electrophysiology and structural heart teams should coordinate with the clinician who understands the patient’s bleeding source, while neurologists and hematologists can clarify competing risks in complex cases.
For clinicians and researchers, the Journal of Arrhythmia provides an open-access setting for reviewing current evidence, procedural developments, and practice-focused research in cardiac electrophysiology. Explore the journal’s arrhythmia literature and contact the editorial team to engage with relevant scientific and educational resources.